Moderators of outcome in late-life depression: A patient-level meta-analysis

American Journal of Psychiatry

Volumn 170, Issue 6, 2013, Pages 651-659

  Nelson, J Craig ^a   Delucchi, Kevin L ^a   Schneider, Lon S ^a  

^a not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; GERIATRIC PATIENT; HAMILTON SCALE; HUMAN; LATE LIFE DEPRESSION; MAJOR DEPRESSION; META ANALYSIS; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW; AGE; AGED; FEMALE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882245351     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12070927     Document Type: Article

References (67)

1. Blazer D, Hughes DC, George LK: The epidemiology of depression in an elderly community population. Gerontologist 1987; 27: 281-287
2. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E: Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157: 729-736
3. Bruce ML, Seeman TE, Merrill SS, Blazer DG: The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. Am J Public Health 1994; 84: 1796-1799
4. Conwell Y: Suicide, in Late Life Depression. Edited by Roose SP, Sackeim HA. Oxford, UK, Oxford University Press, 2004, pp 95-114
5. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW: Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996; 94: 3123-3129
6. Simonsick EM, Wallace RB, Blazer DG, Berkman LF: Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosom Med 1995; 57: 427-435
7. Bruce ML, Leaf PJ, Rozal GP, Florio L, Hoff RA: Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. Am J Psychiatry 1994; 151: 716-721
8. Pulska T, Pahkala K, Laippalla P, Kivelä SL: Major depression as a predictor of premature deaths in elderly people in Finland: a community study. Acta Psychiatr Scand 1998; 97: 408-411
9. Whooley MA, Browner WS; Study of Osteoporotic Fractures Research Group: Association between depressive symptoms and mortality in older women. Arch Intern Med 1998; 158: 2129-2135
10. Nelson JC, Delucchi K, Schneider LS: Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008; 16: 558-567
11. Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB; Fluoxetine Collaborative Study Group: Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Int Psychogeriatr 1995; 7(suppl): 41-53
12. Georgotas A, McCue RE, Cooper T, Chang I, Mir P, Welkowitz J: Clinical predictors of response to antidepressants in elderly patients. Biol Psychiatry 1987; 22: 733-740
13. Nelson JC, Holden K, Roose SP, Salzman C, Hollander SB, Betzel JV: Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets? Int J Geriatr Psychiatry 2007; 22: 999-1003
14. Nelson JC, Mazure CM, Jatlow PI: Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol 1995; 15: 99-105
15. Salzman C: Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. J Clin Psychiatry 1999; 60(suppl 20): 30-33
16. Katon W, Russo J, Frank E, Barrett J, Williams JW Jr, Oxman T, Sullivan M, Cornell J: Predictors of nonresponse to treatment in primary care patients with dysthymia. Gen Hosp Psychiatry 2002; 24: 20-27
17. Mitchell AJ, Subramaniam H: Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry 2005; 162: 1588-1601
18. Roose SP, Sackeim HA, Krishnan KRR, Pollock BG, Alexopoulos G, Lavretsky H, Katz IR, Hakkarainen H; Old-Old Depression Study Group: Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebocontrolled trial. Am J Psychiatry 2004; 161: 2050-2059
19. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M: The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 2003; 160: 2122-2127
20. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB: 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 1991; 148: 345-350
21. Löwe B, Schenkel I, Bair MJ, Göbel C: Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients. J Affect Disord 2005; 87: 271-279
22. Evans M, Hammond M, Wilson K, Lye M, Copeland J: Treatment of depression in the elderly: effect of physical illness on response. Int J Geriatr Psychiatry 1997; 12: 1189-1194
23. Sheikh J, Cassidy EL, Doraiswamy PM, Salomon RM, Hornig M, Holland PJ, Mandel FS, Clary CM, Burt T: Efficacy, safety, and tolerability of sertraline in patients with life-life depression and comorbid medical illness. J Am Geriatr Soc 2004; 52: 86-92
24. Reynolds CF 3rd, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupfer DJ: Maintenance treatment of major depression in old age. N Engl J Med 2006; 354: 1130-1138
25. Gildengers AG, Houck PR, Mulsant BH, Dew MA, Aizenstein HJ, Jones BL, Greenhouse J, Pollock BG, Reynolds CF 3rd: Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharmacol 2005; 25(suppl 1):S8-S13
26. Khan A, Brodhead AE, Kolts RL, Brown WA: Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39: 145-150
27. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a metaanalysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5:e45
28. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53
29. Bosworth HB, Hays JC, George LK, Steffens DC: Psychosocial and clinical predictors of unipolar depression outcome in older adults. Int J Geriatr Psychiatry 2002; 17: 238-246
30. Driscoll HC, Basinski J, Mulsant BH, Butters MA, Dew MA, Houck PR, Mazumdar S, Miller MD, Pollock BG, Stack JA, Schlernitzauer MA, Reynolds CF 3rd: Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 2005; 20: 661-667
31. Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR: Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry 2006; 63: 283-288
32. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC; CREATE Investigators: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-379
33. Flint AJ, Rifat SL: Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Depress Anxiety 1997; 5: 103-107
34. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
35. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W: Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004; 161: 2045-2049
36. Saghafi R, Brown C, Butters MA, Cyranowski J, Dew MA, Frank E, Gildengers A, Karp JF, Lenze EJ, Lotrich F, Martire L, Mazumdar S, Miller MD, Mulsant BH, Weber E, Whyte E, Morse J, Stack J, Houck PR, Bensasi S, Reynolds CF 3rd: Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. Int J Geriatr Psychiatry 2007; 22: 1141-1146
37. Alexopoulos GS, Katz IR, Bruce ML, Heo M, Ten Have T, Raue P, Bogner HR, Schulberg HC,Mulsant BH, Reynolds CF 3rd; PROSPECT Group: Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry 2005; 162: 718-724
38. Nelson JC, Delucchi K, Schneider LS: Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis. Int J Geriatr Psychiatry 2009; 24: 539-544
39. Nelson JC, Devanand DP: A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011; 59: 577-585
40. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, doubleblind, placebo-controlled trial. Lancet 2011; 378: 403-411
41. Kalayam B, Alexopoulos GS: Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999; 56: 713-718
42. Baldwin R, Jeffries S, Jackson A, Sutcliffe C, Thacker N, Scott M, Burns A: Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological, and vascular risk factors. Psychol Med 2004; 34: 125-136
43. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F: Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005; 58: 204-210
44. Sneed JR, Culang ME, Keilp JG, Rutherford BR, Devanand DP, Roose SP: Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression. Am J Geriatr Psychiatry 2010; 18: 128-135
45. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
46. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
47. Bose A, Li D, Gandhi C: Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008; 16: 14-20
48. Hollander M, Wolfe DA: Nonparametric Statistical Methods, 2nd ed. New York, John Wiley & Sons, 1999
49. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, Lawrence Erlbaum, 1988
50. Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Holman S; the Fluoxetine Collaborative Study Group: A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995; 7: 89-104
51. Kasper S, de Swart H, Friis Andersen H: Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005; 13: 884-891
52. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K; Sertraline Elderly Depression Study Group: An 8-week multicenter, parallel-group, double-blind, placebocontrolled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160: 1277-1285
53. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD: Efficacy of controlled-release paroxetine in the treatment of latelife depression. J Clin Psychiatry 2003; 64: 1065-1074
54. Schatzberg A, Roose S: A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006; 14: 361-370
55. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8- week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164: 900-909
56. Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Iyengar M, Carfagno M, Lipschitz A: Low doses of controlledrelease paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2009; 70: 46-57
57. Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD, Wightman DS, O'Leary MC, Millen LS, Leon MC, Briggs MA, Krishen A, Modell JG: Double-blind, placebocontrolled evaluation of extended-release bupropion in elderly patients with major depressive disorder. J Psychopharmacol 2010; 24: 521-529
58. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
59. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
60. Post RM: Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010
61. Duman RS, Monteggia LM: A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59: 1116-1127
62. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV: Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737-746
63. de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, Alves Valle E, de Souza Neto JJ, Mendes Brega R, Magalhães Scoralick F, Araújo Silva S, Martins de Oliveira F, da Costa Júnior AL, Faria Alves VX, Sakurai E: A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord 2007; 24: 36-41
64. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group: Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010; 18: 136-145
65. Dew MA, Whyte EM, Lenze EJ, Houck PR, Mulsant BH, Pollock BG, Stack JA, Bensasi S, Reynolds CF 3rd: Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007; 164: 892-899
66. Klysner R, Bent-Hansen J, Hansen HL, Lunde M, Pleidrup E, Poulsen DL, Andersen M, Petersen HE: Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181: 29-35
67. Wilson KC, Mottram PG, Ashworth L, Abou-Saleh MT: Older community residents with depression: long-term treatment with sertraline: randomised, double-blind, placebo-controlled study. Br J Psychiatry 2003; 182: 492-497